<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327106</url>
  </required_header>
  <id_info>
    <org_study_id>0401129</org_study_id>
    <secondary_id>DGS 2005-01094</secondary_id>
    <nct_id>NCT00327106</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in HIp Fracture Surgery (THIF Study)</brief_title>
  <acronym>THIF</acronym>
  <official_title>Efficacy of Tranexamic Acid on Perioperative Blood Loss During Hip Fracture Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of tranexamic acid in hip fracture
      surgery on the reduction of allogeneic red blood cell transfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies in hip and knee arthroplasty (scheduled surgery) have shown that tranexamic acid
      decreases allogeneic red blood cell transfusion. In hip fracture surgery, an emergent
      procedure, transfusion is frequent. Transfusion increases adverse events such as
      postoperative bacterial infection and venous thrombosis. The purpose of this study is to
      assess the efficacy of tranexamic acid, an anti-fibrinolytic agent, in hip fracture surgery
      on the reduction of allogeneic red blood cell transfusion. The trial will also evaluate if
      the reduction in transfusion will be associated with less postoperative infection and without
      an increase in the thrombotic risk.

      Patients with an isolated hip fracture of less than 48 hours will be randomized to either
      tranexamic acid 15mg/kg IV at skin incision and three hours later or saline.Patients will
      receive fondaparinux for prophylaxis of venous thrombosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients receiving the transfusion of at least one unit of allogeneic red blood cell</measure>
    <time_frame>between the begining of surgery (day 1) and the eighth post-operative day (day 8)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients receiving the transfusion of at least one unit of allogeneic red blood cell</measure>
    <time_frame>between the administration of fondaparinux for venous thrombosis prophylaxis(8 hours after end of surgery on day 1) and the eighth post-operative day (day 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative major hemorrhage</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative blood loss</measure>
    <time_frame>untill day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative bacterial infection (combined criteria of wound infection, bronchopulmonary infection and urinary tract infection)</measure>
    <time_frame>untill six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thromboembolic events (combined criteria of venous thrombo-embolism, stroke, acute coronary syndrome and peripheral arterial thrombosis)</measure>
    <time_frame>untill six weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exacyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiologic serum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid (Exacyl)</intervention_name>
    <description>15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Exacyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient requiring surgery for an isolated hip fracture of less than 48 hours

        Exclusion Criteria:

          -  Contraindication to tranexamic acid

          -  Contraindication to fondaparinux

          -  Contraindication to general anesthesia associated with a femoral nerve block

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Zufferey, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <state>Loire</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <last_update_submitted>June 9, 2009</last_update_submitted>
  <last_update_submitted_qc>June 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Clément CAILLAUX</name_title>
    <organization>Centre Hospitalier Universitaire de Saint-Etienne</organization>
  </responsible_party>
  <keyword>hip fracture</keyword>
  <keyword>transfusion</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>fondaparinux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

